Lipoprotein(a) Drugs: The Race to Lower Lp(a)

Four Drugs, One Target

The race to lower lipoprotein(a) has narrowed to four named candidates, and each one attacks the same gene through a different door. If you can keep the players straight, the entire Lp(a) investing theme becomes easier to follow. The field splits cleanly along the two gene-silencing mechanisms we describe in our gene silencing explainer: antisense and RNA interference.

Two of the four candidates are antisense drugs, and two are RNAi drugs. Both approaches aim at the LPA gene. Both have shown they can crush the biomarker. Where they diverge is in chemistry, dosing schedule, and which company owns them, and those differences matter a great deal to investors.

Pelacarsen: The Antisense Front-Runner

Pelacarsen is the most advanced candidate in the field. It is an antisense oligonucleotide developed by Ionis and licensed to Novartis, and it ran one of the largest cardiovascular outcome trials ever attempted for an Lp(a) drug. That trial enrolled more than 8,300 patients and was the first to put the field’s core question to the test: does lowering Lp(a) actually prevent heart attacks and strokes?

The result, reported in early September 2026, is the single most important data point in the theme. Pelacarsen lowered Lp(a) substantially, but the trial failed to show a reduction in cardiovascular events compared to placebo. We break down what that means for every other Lp(a) drug in our endpoint problem explainer.

Olpasiran: The Amgen RNAi Candidate

Olpasiran is Amgen’s RNAi entry. It binds the LPA messenger RNA through the RISC pathway, the same mechanism Alnylam built its franchise on. Olpasiran is behind pelacarsen on the clinical timeline but has posted strong biomarker reductions in its studies. Amgen’s deep pockets and cardiovascular sales force make it a serious contender even if it is not first to the finish line.

Lepodisiran: Lilly’s RNAi Bet

Lepodisiran is Eli Lilly’s candidate, and it arrived through acquisition. Lilly bought Dicerna, an RNAi platform company, and lepodisiran came out of that deal. Lilly has also partnered with Novo Nordisk on the program, pairing two of the biggest names in metabolic disease behind a single candidate. That kind of backing means lepodisiran will be funded through whatever trials it needs.

Zerlasiran: The Microcap’s Shot

Zerlasiran belongs to Silence Therapeutics, the smallest company in the race. Its RNAi design differs from the others, and its biomarker data has been dramatic, with reductions that have drawn heavy attention. But a 99 percent reduction in the biomarker is not the same as a proven reduction in heart attacks. The distinction is the whole ballgame, and it is worth understanding before getting excited about any single readout.

The Convenience Question

Mechanism is only half the race. The other half is convenience, and here the four candidates do not line up neatly. Antisense drugs like pelacarsen have typically required more frequent dosing than RNAi drugs, which can go months between injections thanks to their potency. A patient asked to take a drug for the rest of their life cares a great deal about whether that means a shot every month, every three months, or twice a year.

That is a real competitive axis, and it could decide the race as much as any single efficacy readout. If two drugs lower Lp(a) by roughly the same amount, the one with the friendliest schedule has an advantage in both trials and commercial adoption. The RNAi entries from Amgen, Eli Lilly, and Silence Therapeutics all aim for long intervals between doses. Pelacarsen’s antisense design is the veteran of the group, but it also carries the oldest dosing assumptions. In a chronic, lifelong indication, convenience is not a footnote. It is a product feature.

The commercial stakes are large because the target population is large. Elevated Lp(a) affects a meaningful share of adults, and there is currently no approved drug that meaningfully lowers it. That is the kind of white space that draws four well-funded companies into the same race, and it is why the competition is likely to get more intense rather than less as the first approvals approach.

For investors, the practical way to track the race is through the outcome trials rather than the biomarker headlines. Biomarker readouts will keep arriving, but after pelacarsen they matter less than the larger studies that measure actual cardiovascular events. The next meaningful catalyst for the theme is a positive event-based readout, and nothing short of that is likely to settle the question.

The Bottom Line

Four drugs are chasing the same genetic target through two mechanisms, and only one has so far put the outcome question to the test. The others are betting that better biomarker reductions, or a different mechanism, will translate into the cardiovascular benefit that pelacarsen’s trial did not show. That is an open question, and it is the single biggest variable in the entire Lp(a) theme.

Ready to see the research? Click here to access Porter Stansberry’s report.

NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.